These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37978138)

  • 1. Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.
    Shapiro GI; Barry SM
    Cancer Treat Res; 2023; 186():207-221. PubMed ID: 37978138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for combining immune checkpoint blockade with PARP inhibition.
    Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
    J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
    Bao Z; Cao C; Geng X; Tian B; Wu Y; Zhang C; Chen Z; Li W; Shen H; Ying S
    Oncotarget; 2016 Feb; 7(7):7629-39. PubMed ID: 26399274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.
    Altwerger G; Ghazarian M; Glazer PM
    Semin Cancer Biol; 2024 Jan; 98():11-18. PubMed ID: 38029867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
    Nambiar DK; Mishra D; Singh RP
    Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Konecny GE; Kristeleit RS
    Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibitor Efficacy Depends on CD8
    Pantelidou C; Sonzogni O; De Oliveria Taveira M; Mehta AK; Kothari A; Wang D; Visal T; Li MK; Pinto J; Castrillon JA; Cheney EM; Bouwman P; Jonkers J; Rottenberg S; Guerriero JL; Wulf GM; Shapiro GI
    Cancer Discov; 2019 Jun; 9(6):722-737. PubMed ID: 31015319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.
    Thein KZ; Thawani R; Kummar S
    Cancer Treat Res; 2023; 186():143-170. PubMed ID: 37978135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
    Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
    Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
    Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
    Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.